Main Products / Services / Pipelines & Platforms
Elixiron Immunotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for autoimmune/neurodegenerative diseases and cancer
Indemakitug (EI-001) • A fully human anti-interferon-γ monoclonal antibody in development for treatment of vitiligo • Potentially first-in-class therapeutic antibody for vitiligo • Well-tolerated in phase I trial • On track to start a proof-on-concept clinical study in vitiligo patients in 2H 2024
Enrupatinib (EI-1071) • A microglia-targeting immunotherapy for treatment of Alzheimer’s disease • Two-time winner of Part-the-Cloud awards from Alzheimer’s Association • Excellent safety profile demonstrated in phase I study • On track to start a proof-on-concept Phase II study in Alzheimer’s patients in 2H 2024
EI-220 • mRNA-based cancer immunotherapy • Novel mechanism of action: to revitalize exhausted T cells by metabolic reprogramming • Unique molecular design enabled by proprietary T-Action Technology • Excellent antitumor efficacy revealed in mouse tumor models; plan to start IND-enabling studies in 2H 2024
Business Interests
▪ We plan to raise series B funding in 2H 2024 to accelerate the development of our clinical assets.
▪ We also welcome the opportunities of out-licensing or co-development.
Contact Info
Chen-Hsuan Ho
Director of Translational Sciences
+886 (2) 27827700 #37
chho@elixiron.com